Skip to main
MDT

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 25%
Buy 40%
Hold 35%
Sell 0%
Strong Sell 0%

Bulls say

Medtronic is expected to see continued growth and increased earnings due to its diverse portfolio, M&A strategy, and potential for expansion in its neurovascular platform. Despite competition and risks from clinical trial results, the company has been rated as a Buy with a price target of $90 based on its success with the Symplicity Spyral RDN System, upcoming separation of its Diabetes segment, and recent acquisitions and partnerships aligning with its strategy for growth.

Bears say

Medtronic is facing several potential headwinds in the near future that may negatively impact their stock performance. These include an increasingly competitive landscape in their electrophysiology (EP) segment, the risk of disruption to their transcatheter aortic valve replacement (TAVR) volumes, and the potential for margin contraction due to continued investments in recent acquisitions and a shift towards lower-margin businesses. Additionally, macroeconomic volatility, especially related to tariffs and currency fluctuations, may also pose a threat to Medtronic's global operations. With these challenges in mind, my outlook for Medtronic is negative as I believe the company may face difficulties in achieving its target EPS growth and could potentially underperform in key end markets.

Medtronic (MDT) has been analyzed by 20 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 40% recommend Buy, 35% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 20 analysts, Medtronic (MDT) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.